Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 5/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | CTSG | P08311 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2622107 | 1.00 | ELANE (0.46) | ELANEHTTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2622091 | 1.00 | ELANE (0.46) | ELANEHTTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2622140 | 1.00 | ELANE (0.46) | ELANEHTTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1933817 | 0.91 | ELANE (0.48) | ELANEF2CTSG | |
| SCHEMBL2622087 | 0.91 | ELANE (0.48) | ELANEF2CTSG | |
| SCHEMBL2622141 | 0.91 | ELANE (0.48) | ELANEF2CTSG | |
| SCHEMBL1934454 | 0.89 | CYP2C19 (0.47) | ELANESMN1; SMN2F2CTSG | |
| SCHEMBL2114953 | 0.89 | KDM4E (0.47) | ELANE | |
| SCHEMBL2622142 | 0.89 | KDM4E (0.47) | ELANE | |
| SCHEMBL1933998 | 0.87 | ELANE (0.45) | ELANEF2CTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2434889-B1 | IAP INHIBITORS | TETRALOGIC BIRINAPANT UK LTD (GB) | 2016-03-09 | — | — | EP | disclosed |
| US-20130274278-A1 | IAP INHIBITORS | TETRALOGIC PHARM CORP (US) | 2013-10-17 | — | — | US | disclosed |
| US-8481495-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-8415486-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120135990-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120094917-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP (US) | 2012-04-19 | — | — | US | disclosed |
| EP-2434889-A1 | IAP INHIBITORS | Tetralogic Pharmaceuticals Corp. (US) | 2012-04-04 | — | — | EP | disclosed |
| EP-2434890-A1 | IAP INHIBITORS | Tetralogic Pharmaceuticals Corp. (US) | 2012-04-04 | — | — | EP | disclosed |
| WO-2010138496-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138666-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135990-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | ELANE 692/4885HTT 786/4885NPC1 757/4885 |
| US-20130274278-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | ELANE 692/4885HTT 786/4885NPC1 757/4885 |
| US-20120094917-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | ELANE 692/4885HTT 786/4885NPC1 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.